LTβR-Ig fusion protein changed lymphocyte trafficking and reduced inflammatory markers in line with its expected mechanisms of action, but not producing considerable clinical efficacy in rheumatoid arthritis or Sjögren's syndrome (St Clair et al. 2018). The gene discussed is LTBR; the disease is rheumatoid arthritis.